Full-Time

Quality Assurance and Regulatory Affairs Specialist

EMED Technologies

EMED Technologies

11-50 employees

Subcutaneous infusion systems for home care

No salary listed

New York, NY, USA

In Person

Bachelor's

Category
QA & Testing
Risk & Compliance
Legal
Manufacturing Quality & Test (1)

Get referred to EMED Technologies

See people who can refer or advise you

Requirements
  • Bachelor’s degree with desired areas including Science, Engineering or related field
  • Minimum of 3 years of experience in Quality Assurance in pharmaceutical and/or medical device industries
  • Knowledge of MS Office Suite (Excel, Word, Outlook)
  • Excellent interpersonal skills, ability to meet deadlines, manage priorities and work well under pressure
  • Ability to work in a self-directed manner and confidently deal with ambiguous issues to drive towards suitable actions
Responsibilities
  • Administration of Document Control function, including document ID issuance, revision control, coordination of review and approval, communication of implementation tasks, and maintenance of all records.
  • Administration of Document Control function, including document ID issuance, revision control, coordination of review and approval, communication of implementation tasks, and maintenance of all records.
  • Lead/assist with Corrective and Preventative Action (CAPA) investigations, plan development and implementation of corrective actions, author CAPA reports, and ensure completion and accuracy of all associated Quality records.
  • Support nonconforming product handling and disposition assessments and manage all records.
  • Coordinate the efficient handling and resolution of Customer Complaints, working with contract manufacturer sites and other EMED departments, and manage all records.
  • Perform reporting and trending on Quality metrics to ensure an oversight of the compliance landscape for the site.
  • Support external audits/inspections with audit readiness preparations, back-room support and response writing to non-conformances.
  • May serve as an Internal/Supplier Auditor and conduct audits per schedule
  • Write new and revise existing QMS standard operating procedures as directed.
  • Review, approve, and maintain device history record files.
  • Identify, initiate, and lead process and compliance improvement as requested.
  • Interface with other EMED departments such as Engineering, Operations, Customer Service, and Regulatory Affairs as necessary to ensure success for assigned responsibilities.
  • Support various Quality Assurance activities as assigned under minimal supervision/instruction.
  • Assist with Regulatory Affairs tasks as assigned
  • Ensure that all Quality Assurance related tasks and responsibilities defined in EMED Quality Management System Documentation are performed, as defined.

EMED Technologies manufactures medical devices and drug delivery systems specifically for subcutaneous infusion of biologics and specialty drugs. Its products, such as the SCIg60 system and VersaPump, use mechanical syringe pumps and variable flow rate controllers to allow patients to safely administer medication at home. Unlike many competitors, the company provides a complete end-to-end B2B solution that includes device design, AI-monitored manufacturing, and final packaging for pharmaceutical partners. The company's goal is to increase patient independence and quality of care by providing accessible, home-based infusion platforms across global markets.

Company Size

11-50

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$8M

Headquarters

California

Founded

1987

Get referred to EMED Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • February 24, 2026, EMED closed an $8 million equity financing.
  • September 3, 2025 patent issuance broadens VersaRate protection and strengthens licensing leverage.
  • August 2025 advisory board and December 2025 Tetra clearance validate EMED's platform relevance.

What critics are saying

  • EMED's growth still depends on patent fights against RMS Medical Products.
  • The 2026 subsidiary financing signals capital hunger before broader expansion completes.
  • Tetra 510(k) approval for competitor Emed Technologies on December 22, 2025 pressures pricing.

What makes EMED Technologies unique

  • EMED owns subcutaneous infusion IP, including VersaRate's September 2025 patent expansion.
  • Its SCIg60 and AccuSert platforms target home-based biologics delivery, not generic pumps.
  • EMED couples device design, manufacturing, labeling, and packaging for pharma partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
PR Newswire
Feb 24th, 2026
EMED Subsidiary Closes $8 Million Equity Financing

/PRNewswire/ -- Today, EMED Technologies, a global leader in drug delivery and innovative infusion therapy devices announced that its subsidiary closed a...

PR Newswire
Sep 30th, 2025
eMed Population Health Appoints Dr. Dyan Hes as Chief Medical Officer

MIAMI, Sept. 30, 2025 /PRNewswire/ - eMed Population Health, Inc. today announced the appointment of Dr. Dyan Hes as Chief Medical Officer.

Morningstar
Sep 8th, 2025
eMed Population Health Appoints Renowned Industry Leader Amy Elkins as Chief Operating Officer

MIAMI, Sept. 8, 2025 /PRNewswire/ - eMed Population Health, Inc. today announced the appointment of Amy Elkins as Chief Operating Officer.

Investing.com
Aug 18th, 2025
Aon invests in eMed to expand GLP-1 weight management programs By Investing.com

Aon invests in eMed to expand GLP-1 weight management programs

PR Newswire
May 5th, 2025
Emed Announces Collaboration With Aon To Provide A Digital Glp-1 Benefit Program For Aon Colleagues

Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity managementMIAMI, May 5, 2025 /PRNewswire/ -- eMed®, the leading Population Health technology platform in remote chronic care management and 24/7/365 live care, today announced an industry-changing collaboration with leading global professional services firm, Aon , to provide GLP-1 obesity management services for the company's U.S. employees.This collaboration builds off the momentum from Aon's recently released findings showing a seven percentage point reduction in the growth of medical spend in the second year of GLP-1 therapy, and a 44 percent reduction in risk of hospitalizations caused by major adverse cardiovascular events with adherent GLP-1 utilization. Both eMed and Aon are committed to improving population health by accessible, personalized, and effective healthcare solutions that support better health outcomes and address critical issues such as obesity, diabetes, and related comorbidities."We are thrilled to collaborate with Aon to bring our cutting-edge platform to their employees," said Dr. Patrice Harris, CEO of eMed. "Our platform is a science-based, all-in-one solution proven to deliver superior health outcomes for participants, while enabling employers to manage their spend on GLP-1s. Together with Aon, we're not just offering access to GLP-1s; we're ensuring they are used effectively to improve long-term employee health outcomes as demonstrated by Aon's groundbreaking analysis.""Our findings show that GLP-1s, when combined with holistic support like nutrition, exercise and mental health resources, can deliver lasting health improvements